Xu, Y., Chen, M., Gao, X., Liu, X., Zhao, J., Zhong, W., Pan, R., Wang, M. (2025). Phase 2 study of pembrolizumab (pembro) plus plinabulin (plin) and docetaxel (doc) for patients (pts) with metastatic NSCLC after progression on first-line immune checkpoint inhibitor alone or combination therapy: Initial efficacy and safety results on immune re-sensitization.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.8560